ASH Annual Meeting Abstracts
ASH Introduces Changes to Abstract Submissions
Prospective abstract submitters should take note of several changes for the 2024 ASH Annual Meeting.
- No figures or tables may be included in abstract submissions. This change is being made for greater consistency and efficiency in the review process. While only text is allowed in abstracts, figures and/or tables may be included in the oral and poster presentations for abstracts accepted to the program.
- Demographic information about clinical trial enrollments is requested. Given the importance of clinical trial enrollment reflecting the spectrum of the general population at risk for the disease under investigation, ASH requests that demographic information regarding, sex, gender, race, ethnicity, age, disability, or other relevant factors of enrolled subjects be included in an oral or poster presentation, when available. If some or all information is not available, ASH asks that presenters disclose in their oral or poster presentation the limitations that led to such data not being collected.
- Authors must acknowledge research integrity. Submitters will be asked to acknowledge via a checkbox on the submission form that “ASH expects all scientific research submitted or presented as part of the abstract program to conform to the generally accepted standards of scientific integrity regarding experimental design, data collection, analysis, and interpretation."
Abstracts submitted for oral and poster presentation at the ASH annual meeting represent important, novel research in the field and are considered the best of the thousands of abstracts submitted. Typically, more than 7,000 scientific abstracts are submitted each year, and more than 5,000 abstracts are accepted for oral and poster presentations through an extensive peer review process.
Abstract categories are reviewed and updated annually to respond to trends and cover new areas. This year, updates include
- The renumbering of categories (particularly those in the 600 and 900 groupings)
- The discontinuation of two categories (731. Autologous Transplantation, and 705. Cellular Immunotherapies: Commercial and Late Stage)
- The addition of several new categories (909. Education, Communication, and Workforce, 628. Aggressive Lymphomas: Cellular Therapies, and 655. Multiple Myeloma: Cellular therapies)
- The splitting of several categories (including several in thrombosis and homeostasis, clinical lymphomas, and health services, quality improvement and outcomes research).
View the full list of abstract categories.
The Plenary Scientific Session, which includes the top six abstracts as selected by the Program Committee, is traditionally a highlight of the annual meeting program.
Key Dates and Deadlines
| Abstract submission site opens | May 30, 2024 |
| Abstract submission deadline | August 1, 2024, 11:59 p.m. Pacific time |
| Abstract withdrawal deadline | September 18, 2024 |
| Call for late-breaking abstract submissions | October 16-28, 2024 |
| Abstracts available online | November 5, 2024, 9:00 a.m. Eastern time |
| Abstract poster presentation materials due | November 12, 2024 |
| Late-breaking abstracts available online | November 25, 2024, 9:00 a.m. Eastern time |